Objectives:

1. Review published data with SGLT2 and SGLT1/2 inhibitors in type 1 diabetes.

2. Review published data on DKA as a complication of SGLT inhibition in type 1 diabetes.

3. Be able to discuss risks and benefits of SGLT inhibition in type 1 diabetes.

Session date: 
Monday, May 7, 2018 - 5:00pm to 6:00pm
Speaker Name: 
John B. Buse, M.D., Ph.D.
Location: 
UCMC M-170
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.